Abstract

The present provides a condensed pyridine compound (I) represented by the following formula:

$$R^1$$
 A
 R^3
 $(CH_2)_n$
 $(CH_2)_n$
 (I)

(wherein, R² represents

$$+N$$
 $T-R^4$
 $+N$
 R^5
 $-N$

ring A represents benzene ring, pyridine ring, thiophene ring or furan ring; and

B represents

$$(O)z \longrightarrow \mathbb{R}^{7}$$

$$Q \longrightarrow \mathbb{R}^{10}$$

$$Q \longrightarrow \mathbb{R}^{10}$$

$$Q \longrightarrow \mathbb{R}^{12}$$

$$Q \longrightarrow \mathbb{R}^{12}$$

$$Q \longrightarrow \mathbb{R}^{13}$$

$$Q \longrightarrow \mathbb{R}^{14}$$

$$Q \longrightarrow \mathbb{R}^{15}$$

$$Q \longrightarrow \mathbb{R}^{16}$$

$$Q \longrightarrow \mathbb{R}^{16}$$

$$Q \longrightarrow \mathbb{R}^{16}$$

its pharmaceutically acceptable salt or hydrates thereof, which is a clinically useful medicament having a serotonin antagonism, in particular, that for treating, ameliorating or preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.